- Nutriband Inc. has signed an addendum to its agreement with Kindeva Drug Delivery, a CDMO, to advance the development of its abuse-deterrent fentanyl patch, AVERSA Fentanyl.
- The updated agreement formalises their exclusive partnership and long-term commitment, incorporating shared development costs in exchange for milestone payments.
Nutriband Inc. has expanded its collaboration with Kindeva Drug Delivery, a contract development and manufacturing organisation (CDMO), by signing an addendum to their Commercial Development and Clinical Supply Agreement. The agreement focuses on the continued development of AVERSA Fentanyl, a transdermal patch designed to deter opioid abuse, misuse, and accidental exposure.
The revised agreement formalises their exclusive product development partnership, reinforcing a long-term commitment between the two companies. Under the new terms, both parties will share development costs, with Nutriband making milestone payments to Kindeva.
AVERSA is an abuse-deterrent transdermal technology that integrates aversive agents into patches to prevent misuse. The proprietary coating technology leverages taste aversion to discourage oral abuse and accidental exposure to opioid and stimulant patches.
The AVERSA platform is protected by an international patent portfolio spanning 46 countries, including the United States, Europe, Japan, Korea, Russia, China, Canada, Mexico, and Australia. According to Nutriband, AVERSA Fentanyl has the potential to become the first opioid patch of its kind and could generate peak annual U.S. sales of $80 million to $200 million.
Stay ahead of trends and best practices
